System for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response
Abstract
A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.
Term
Term ended
Projected expiry passed 6 July 2020, 6.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
58 members in 16 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 34859299 | United States of America | A |
Members58
| Document | Office | Kind | |
|---|---|---|---|
| CA2362429A1 | Canada | A1 | |
| WO0102050A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5919800A | Australia | A | |
| US6267116B1 | United States of America | B1 | |
| US2001018919A1 | United States of America | A1 | |
| US2001020475A1 | United States of America | A1 | |
| CA2404517A1 | Canada | A1 | |
| WO0174084A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5121501A | Australia | A | |
| US2001042551A1 | United States of America | A1 | |
| US2001050920A1 | United States of America | A1 | |
| NO20020043D0 | Norway | D0 | |
| NO20020056D0 | Norway | D0 | |
| NO20020056L | Norway | L | |
| WO0102050A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO0174084A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO0174084B1 | World Intellectual Property Organization (WIPO) | B1 | |
| CA2419431A1 | Canada | A1 | |
| WO0219935A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU8486801A | Australia | A | |
| BR0012241A | Brazil | A | |
| EP1191894A2 | European Patent Office (EPO) | A2 | |
| KR20020036790A | Republic of Korea | A | |
| MXPA01013306A | Mexico | A | |
| CN1359276A | China | A | |
| IL147201A0 | Israel | A0 | |
| IL147201D0 | Israel | D0 | |
| TR2001003831T2 | Türkiye | T2 | |
| TR200103831T2 | Türkiye | T2 | |
| WO02082972A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO02082972A9 | World Intellectual Property Organization (WIPO) | A9 | |
| EP1273174A2 | European Patent Office (EPO) | A2 | |
| JP2003503165A | Japan | A | |
| CA2455455A1 | Canada | A1 | |
| WO03011215A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2002322611A1 | Australia | A1 | |
| WO02082972A3 | World Intellectual Property Organization (WIPO) | A3 | |
| IL151950A0 | Israel | A0 | |
| IL151950D0 | Israel | D0 | |
| EP1311202A1 | European Patent Office (EPO) | A1 | |
| US6575169B2 | United States of America | B2 | |
| US6581606B2 | United States of America | B2 | |
| US6581607B2 | United States of America | B2 | |
| WO03011215A3 | World Intellectual Property Organization (WIPO) | A3 | |
| CA2401913A1 | Canada | A1 | |
| NZ521644A | New Zealand | A | |
| EP1191894A4 | European Patent Office (EPO) | A4 | |
| CA2362429C | Canada | C | |
| AU2001251215B2 | Australia | B2 | |
| US6942614B1 | United States of America | B1 | |
| US7100193B2 | United States of America | B2 | |
| EP1311202A4 | European Patent Office (EPO) | A4 | |
| EP1191894B1 | European Patent Office (EPO) | B1 | |
| AT378015T | Austria | T | |
| ATE378015T1This record | Austria | T1 | |
| DE60037116D1 | Germany | D1 | |
| DE60037116T2 | Germany | T2 | |
| CA2455455C | Canada | C |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 945223
Titles2
- German
- SYSTEM ZUR BEHANDLUNG EINES PATIENTEN MIT EINEM MEDIKAMENT ZUR OPTIMIERUNG DER THERAPIE UND ZUR VERHINDERUNG EINES NEGATIVEN NEBENEFFEKTES
- English
- SYSTEM FOR TREATING A PATIENT WITH A MEDICATION TO OPTIMIZATE THERAPY AND PREVENT A NEGATIVE SIDE EFFECT
Classification
- CPC, 1
- A61K49/0004
- IPC, 4
- A61J3 00
- A61G12 00
- A61K49 00
- G06F19 00